Abatacept · Orencia
Protein / enzyme therapeutic
Evidence outlook
Approved: Psoriatic Arthritis, Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (5)
- Prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in patients undergoing hematopoietic stem cell transplantation
- Polyarticular Juvenile Idiopathic Arthritis ORENCIA is indicated for the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA).
- Treatment of rheumatoid arthritis (for use only in patients who have not sufficiently responded to conventional treatments)
- Rheumatoid arthritis Orencia, in combination with methotrexate, is indicated for: the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor. the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate. A reduction in the progression of joint damage and improvement of physical function have been...
- Adult Rheumatoid Arthritis (RA) ORENCIA (abatacept) is indicated in the treatment of Rheumatoid Arthritis for: 1. reducing signs and symptoms 2. inducing clinical responses ORENCIA may be also used long-term, to inhibit the progression of structural damage, and improve physical function in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs or to TNF antagonists or to both. ORENCIA may be administered by Intravenous (IV) or Subcutaneous (SC) route (see 4 DOSAGE AND ADMINISTRATION). It is expected, based on...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00048568 NCT00048568 · Rheumatoid Arthritis This was a randomized, double-blind, placebo-controlled Phase III trial with 652 randomized and treated participants (433 abatacept + MTX, 219 placebo + MTX) and adequate power for its primary endpoint. The primary ACR20 response at Day 169 was met (288/424 vs 85/214, p<0.001), as were co-primary HAQ response and radiographic erosion change at Day 365 (p<0.001 and p=0.029). These are hard clinical/functional and radiographic structural endpoints, not surrogate biomarkers. Placebo-controlled add-on to methotrexate: the registry title reads 'Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study'; 'active-controlled' comes from the methotrexate background arm. 652 patients started the double-blind period (433 abatacept + methotrexate, 219 placebo + methotrexate); the registry's enrolment field says 1,250. Registry: NCT00048568 | 3 | Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169; Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire (HAQ) at Day 365; Baseline and Mean Change From Baseline (BL) in Radiographic Erosion Score Results at Day 365 (BL (Day 0), Day 365); Participants With Deaths, Adverse Events (AEs) and SAEs in the Open-Label (OL) Period (Day 365 to Day 2,185); Participants With Hematology Values Meeting the Marked Abnormality Criteria in the OL Period (Day 365 to Day 2,185); Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria in the OL Period (Day 365 to Day 2,185); Participants With Electrolyte Values Meeting the Marked Abnormality Criteria in the OL Period (Day 365 to Day 2,185); Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting the Marked Abnormality Criteria in the OL Period (Day 365 to Day 2,185); Mean BL Immunoglobulins Over Time in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093); Mean Change From BL in Immunoglobulins in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093); Participants With Immunogenicity to Abatacept in the Cumulative DB + OL Period (Day 1 to Day 1,821); Number of Participants Experiencing Clinically Significant Changes in Vital Signs in the OL Period (Day 365 to Day 1,821. All changes in participant vital signs were monitored on each day of study drug administration prior to dosing and 60 minutes after dosing.); Number of Participants Experiencing AEs of Special Interest in the OL Period (Day 365 to Day 2,185); Mean BL Hematocrit in the OL Period (Baseline (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Participant Hematocrit in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL Platelet Count in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Participant Platelet Count in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL Hemoglobin, Total Protein, and Albumin in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Hemoglobin, Total Protein, and Albumin in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL White Blood Cells in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in White Blood Cells in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL Liver Function Parameters in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Liver Function Parameters in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL Select Laboratory Parameters in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Select Laboratory Parameters in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL Serum Electrolytes in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Serum Electrolytes in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185) 2009-10 | Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169): ABA + MTX DB 288/424 (67.9%) vs MTX + Placebo DB 85/214 (39.7%) | Reliable signal | link ↗ |
View 6 more trials
NCT00048581 NCT00048581 · Rheumatoid Arthritis This was a randomized, double-blind, placebo-controlled Phase III trial in 391 patients with rheumatoid arthritis who had failed anti-TNF therapy. The primary endpoints were ACR20 response and HAQ response at Day 169, both clinical measures, and the trial was adequately powered (96% power for the ACR20 comparison). Abatacept was significantly superior to placebo on both primary endpoints: ACR20 response occurred in 129/256 (50%) vs 26/133 (20%) patients, p<0.001, and clinically meaningful HAQ improvement occurred in 121/256 (47%) vs 31/133 (23%), p<0.001. 391 patients started the double-blind period (258 abatacept, 133 placebo); the registry's enrolment field says 738. Registry: NCT00048581 | 3 | Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169; DB; Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire (HAQ) (Day 169); Open-Label Period (OL); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation (From first day of OL to 5.5 years); OL; Number of Participants AEs of Special Interest (From first day of OL to 5.5 years); OL; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria (From first day of OL to 5.5 years); OL; Number of Participants With Blood Chemistry Laboratories Meeting Marked Abnormality Criteria (From first day of OL to 5.5 years); OL; Mean Time-matched Baseline Immunoglobulin (Ig) Levels Over the OL (Baseline and Days 169, 365, 729, and 1093); OL; Mean Time-matched Change From Baseline in Immunoglobulin (Ig) Levels Over the OL (BL, Days 169, 365, 729, and 1093) 2009-09 | Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169): Abatacept (ABA) 129/256 (50.4%) vs Placebo (PLA) 26/133 (19.5%) | Reliable signal | link ↗ |
NCT00279760 NCT00279760 · Rheumatoid Arthritis Registry: NCT00279760 | 1/2 | Assess the relative safety and preliminary efficacy (clinical activity) of BMS-188667 and BMS-224818 in subjects with rheumatoid arthritis (RA) 2002-03 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT00162266 NCT00162266 · Rheumatoid Arthritis This was a randomized, quadruple-blind, placebo-controlled trial of 339 randomized patients with rheumatoid arthritis; adding abatacept 10 mg/kg to methotrexate produced ACR20 responses in 70/115 (60.9%) versus 42/119 (35.3%) with placebo at day 180 (p<0.001), a clear positive result. However, no sample-size or power calculation was reported, so the trial cannot be confirmed as adequately powered, and the registry lists 524 enrolled with only 339 randomized. Registry: NCT00162266 | 2 | Number of Responders to American College of Rheumatology 20% Improvement Criteria (ACR 20) at Day 180 of the Double-Blind (DB) Period; Participants Receiving Concomitant Disease Modifying Rheumatic Drugs and Biologics in Open-Label (OL) Period (Day 360 to Day 3,060); Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) in OL Period (Day 360 to Day 3060); Number of Participants With AEs of Special Interest in OL Period (Day 360 to Day 3060); Baseline Serum Immunoglobulin A (IgA) Over Time in OL Period (Baseline (Day 0) and Days 360, 720,1080, 1440, and 1800); Mean Change From Baseline (BL) in IgA Over Time in OL Period (Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800); Baseline Immunoglobulin G (IgG) Over Time in OL Period (Baseline (Day 0) and Days 360, 720, 1080, 1440 and 1800); Mean Change From Baseline (BL) in IgG Over Time in OL Period (Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800); Baseline Immunoglobulin M (IgM) Over Time in OL Period (Baseline (Day 0) and Days 360, 720,1080,1440, and 1800); Mean Change From Baseline (BL) in IgM in OL Period (Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800); Number of Participants With Hematology Values Meeting Marked Abnormality Criteria in OL Period (Day 360 to Day 3060); Number of Participants With Liver and Kidney Function Values Meeting Marked Abnormality Criteria in OL Period (Day 360 to Day 3060); Number of Participants With Electrolyte Values Meeting Marked Abnormality Criteria in OL Period (Day 360 to Day 3060); Number of Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting Marked Abnormality Criteria in OL Period (Day 360 to Day 3060) 2009-09 | ACR 20 at Day 180 (double-blind period): abatacept 10 mg/kg + methotrexate 70/115 vs placebo + methotrexate 42/119, difference 25.6 percentage points (95% CI 12.8 to 38.4), p<0.001; abatacept 2 mg/kg + methotrexate 44/105, difference 6.6 (95% CI -6.2 to 19.4), p=0.31 (CT.gov posted results). | Partial signal | link ↗ |
NCT00048932 NCT00048932 · Rheumatoid Arthritis This was a large randomized, double-blind, placebo-controlled trial, but every primary endpoint measured safety and tolerability rather than whether abatacept improves arthritis. It gives controlled safety information without testing efficacy. Registry: NCT00048932 | 3 | Double Blind Period (DB); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation (Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication); DB; Number of Participants With AEs of Special Interest (Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication); DB; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria (Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication); DB; Number of Participants With Blood Chemistry Laboratories Meeting Marked Abnormality (MA) Criteria (Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication); DB; Number of Participants With Clinically Significant Physical Examination or Vital Signs Abnormalities (Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337. Vital signs were measured at these visits before and after study medication infusion.); Open Label Period (OL); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation (Day 365 to Day 1,821); OL; Number of Participants With AEs of Special Interest (Day 365 to Day 1821); OL; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria (Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication); OL; Number of Participants With Liver Function Laboratories Meeting Marked Abnormality Criteria (Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication); OL; Number of Participants With Electrolyte Laboratories Meeting Marked Abnormality Criteria (Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication); OL; Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting Marked Abnormality Criteria (Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication); OL; Number of Participants With Clinically Significant Physical Examination or Vital Signs Abnormalities (Days 365 to Day 1821) 2009-10 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT00122382 NCT00122382 · Rheumatoid Arthritis The study was randomized and double-blind, compared abatacept plus methotrexate with placebo plus methotrexate, and randomized 511 participants. Both primary efficacy endpoints were statistically favorable for abatacept at 12 months, but the available record does not report a sample-size or power calculation, so the evidence is presented as moderate rather than strong. Registry: NCT00122382 | 3 | Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12; Mean Change From Baseline in Radiographic Total Score to Month 12 (Baseline, Month 12); Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label Period (Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.); Number of Participants With Serious Adverse Events Reported During the Open-Label Period (Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.); Number of Participants With SAEs With an Outcome of Death During the Open-label Period (Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.); Incidence Rates of Autoimmune Disorders in ABA-Treated Participants (Double Blind Period (+56 days post last dose in double-blind period or start of open-label period, whichever came first). Open-label period (56 days post last dose in the open-label period or start of maintenance sub-study, whichever came first).); Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated Participants (Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).); Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated Participants (Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).); Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label Period (Open-Label Period (Month 12 to Month 24)); Number of Participants With Select Blood Chemistry Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period (Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.); Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period (Continuously from start of open-label period up to 56 days post the last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.) 2008-02 | DAS28-CRP remission at Month 12: abatacept + methotrexate 106/256 vs placebo + methotrexate 59/253, difference 18.1 percentage points (95% CI 9.6 to 26.6), p<0.001. Co-primary radiographic total score change to Month 12: 0.63 vs 1.06 units, p<0.040 (non-parametric ANCOVA) (CT.gov posted results). | Partial signal | link ↗ |
NCT00559585 NCT00559585 · Rheumatoid Arthritis This was a large randomized, double-blind trial comparing subcutaneous abatacept against the established intravenous form, with ACR20 response as the primary endpoint. The difference in ACR20 response was 0.3% with a confidence interval well inside the prespecified non-inferiority margin, a sample size calculation required 1,440 patients, and 1,457 were randomized and treated. Registry: NCT00559585 | 3 | Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169; Anti-TNF Failure Sub-Study Double Blind Period : Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Response in Anti-TNF Failure Population (Days 85, and 169 and postvisits on Days 28, 56, and 85) 2009-11 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (49)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (56)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (28)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (25)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (6)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Studied as part of a combination product (1)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 2/3 (1)
What this study did
Appears in other studies (2)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 4 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Psoriatic Arthritis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Abatacept (Orencia): this drug | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), CD80/CD86 (B7-1/B7-2) on antigen-presenting cells, Selective T Cell Costimulation Modulator | Reliable signal | NCT01860976: Proportion of ACR 20 Responders at Day 169 (Day 169): Abatacept 39.4% (95% CI 32.9 to 46) vs Placebo 22.3% (95% CI 16.7 to 27.9) | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | Reliable signal | NCT01212770: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 28.4% | Apremilast 30 mg 40.7% vs Placebo 18.3% NCT01172938: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 30.4% | Apremilast 30 mg 38.1% vs Placebo 19% | |
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | Reliable signal | NCT03896581: ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results). NCT03895203: ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results). | |
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | Weak signal | No reviewed efficacy summary in this indication | |
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | Reliable signal | NCT04908189: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002 NCT04908202: POETYK PsA-1 (NCT04908202), primary endpoint ACR20 at week 16: met, p<0.0001 | |
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | Reliable signal | NCT02376790: ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005) NCT00317499: ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001) | |
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | NCT02181673: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% phase 3 result · pivotal pending | |
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT04882098: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants NCT03162796: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (Week 24): Guselkumab 100 mg q8w 52% | Guselkumab 100 mg q4w 59.4% vs Placebo 22.2% | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Ixekizumab (Taltz) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT02349295: ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001 NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo. | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03675308: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8) | |
| Secukinumab (Cosentyx) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT04632927: HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002. NCT02404350: ACR20 at week 16: secukinumab 300 mg load 62.6%, 150 mg load 55.5%, 150 mg no load 59.5% vs placebo 27.4%; odds ratios 4.58 (95% CI 3.16 to 6.63), 3.38 (2.35 to 4.87) and 4.02 (2.78 to 5.79), all p<0.0001 (CT.gov posted results). | |
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | Partial signal | No reviewed efficacy summary in this indication | |
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03104400: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5) NCT03104374: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 56.9% (95% CI 50.2 to 63.6) | Upadacitinib 30 mg 63.8% (95% CI 57.4 to 70.1) vs Placebo 24.1% (95% CI 18.3 to 29.8) | |
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aekn (Selarsdi) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Auub (Wezlana) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Hmny (Starjemza) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Srlf (Imuldosa) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Stba (Steqeyma) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Ttwe (Pyzchiva) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Icotrokinra (Icotyde) | Phase 3 | Peptide | IL-23 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Netakimab | Phase 3 | Monoclonal antibody | IL-17 | Reliable signal | NCT03598751: ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo. | |
| Sonelokimab | Phase 3 | Antibody-derived scaffold | IL-17A/F | Partial signal | NCT06641076: Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52). NCT05640245: ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled) | |
| Tirzepatide (Zepbound) | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Vunakizumab | Phase 3 | Monoclonal antibody | IL-17 | Partial signal | NCT05055934: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively | |
| Zasocitinib | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10374 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| TQH3906 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| LPX-TI641 | Phase 1 | Small molecule | TIM receptor (Treg-expanding) | not yet graded | No reviewed efficacy summary in this indication | |
| S-4321 | Phase 1 | Multispecific antibody | PD-1 / FcγRIIb (dual) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(21 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Orencia (Abatacept) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.